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Key questions
What is already known?
 Ź Care- seeking cascades for people with tuberculosis 
(TB) disease have mainly been investigated in low- 
income and middle- income countries and relied on 
cross- sectional data that do not include details of 
patient interactions with health systems and their 
timing.
 Ź Patient pathway analysis methods have been intro-
duced to identify misalignment of TB service provi-
sion with patient demand using cross- sectional data 
from disparate sources.
 Ź Under universal health coverage, routine health in-
surance data in Taiwan capture detailed individual 
records, but events require interpretation to recon-
struct individual patient pathways.
What are the new indings?
 Ź To analyse these data, we developed a new individ-
ual patient pathway analysis (IPPA) framework and 
explored the temporal patterns, complexity and het-
erogeneity of TB patient pathways.
 Ź Applying IPPA to the Taiwan data from 2000 to 2010, 
we found huge heterogeneity in pathways driven by 
the interruption of evaluation and re- evaluation: 10% 
of the pathways had delays of over 200 days be-
tween initial care- seeking and treatment initiation, 
while the median delay was 41 days.
What do the new indings imply?
 Ź Routinely collected data can help understand the 
care- seeking of patients with TB.
 Ź Understanding the causes of interrupted evaluation 
should be a focus of further investigation in Taiwan. 
Lower attention to TB as a cause of illness with de-
clining burden may play a role in this setting.
AbsTrACT
Introduction Patients with tuberculosis (TB) often 
experience dificulties in accessing diagnosis and 
treatment. Patient pathway analysis identiies mismatches 
between TB patient care- seeking patterns and service 
coverage, but to date, studies have only employed cross- 
sectional aggregate data.
Methods We developed an algorithmic approach to 
analyse and interpret patient- level routine data on 
healthcare use and to construct patients’ pathways from 
initial care- seeking to treatment outcome. We applied 
this to patients with TB in a simple random sample of one 
million patients’ records in the Taiwan National Health 
Insurance database. We analysed heterogeneity in pathway 
patterns, delays, service coverage and patient lows 
between different health system levels.
results We constructed 7255 pathways for 6258 patients. 
Patients most commonly initially sought care at the primary 
clinic level, where the capacity for diagnosing TB patients 
was 12%, before eventually initiating treatment at higher 
levels. Patient pathways are extremely heterogeneous 
prior to diagnosis, with the 10% most complex pathways 
accounting for 48% of all clinical encounters, and 55% 
of those pathways yet to initiate treatment after a year. 
Extended consideration of alternative diagnoses was 
more common for patients aged 65 years or older and for 
patients with chronic lung disease.
Conclusion Our study demonstrates that longitudinal 
analysis of routine individual- level healthcare data can 
be used to generate a detailed picture of TB care- seeking 
pathways. This allows an understanding of several 
temporal aspects of care pathways, including lead times to 
care and the variability in patient pathways.
InTroduCTIon
Tuberculosis (TB) is a curable infectious 
disease but has become the world’s leading 
infectious killer with unacceptably slow 
progress towards meeting global targets laid 
out in the End TB strategy.1 These targets 
include the elimination of catastrophic costs 
due to TB,2 in recognition of the financial 
impact TB illness and care- seeking imposes 
on households.3 One of the key gaps in TB 
control is the ‘missing millions’: 4 in 10 
people developing TB globally are either not 
diagnosed and treated, or are not notified to 
national tuberculosis programmes (NTPs).1 
Understanding the health system pathways of 
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Figure 1 Patient pathway construction bars show patient 
states in three domains where non- zero. Background colours 
show the stage label within a pathway. (A) Basic patient 
pathway: (1) corresponds to initial care- seeking; (2) and 
(3) represent escalating clinical consideration of TB; (4) is 
treatment initiation; and (5) represents diagnostic evaluation 
while on anti- TB treatment. (B) Separated evaluation series. 
Considering there is no count in related illness dimension, 
the evaluation (6) would be dropped as separated by 
longer than 60 days, and the pathway would begin at 
(7). (C) Interrupted evaluation. With evidence of clinician 
consideration of a related illness, the evaluation at (8) is 
included in the pathway. TB, tuberculosis.
patients who are seeking care for TB is key in identifying 
low- hanging fruit for TB control: programmatic short-
comings that mean patients are either missed, not noti-
fied or incur ruinous expense in their efforts to obtain 
care.
Cascade of care analyses for TB have addressed the 
drop- offs at different stages from those needing treat-
ment through to those completing treatment for active 
tuberculosis4 and for latent TB infection.5 This work has 
recently been extended with the introduction of patient 
pathway analysis (PPA) for TB,6 which provides a stan-
dardised analysis approach for drawing together data 
from different sources to identify misalignment between 
capacity for TB diagnosis and treatment, and patients’ 
preferences in seeking care.7 Initial work was undertaken 
in five countries8–12 and notably found low coverage of 
diagnostic capacity for TB at facilities where patients 
typically first present.13 This work has argued that more 
needs to be done to ‘meet the patients where they are’,14 
in line with the patient- centred care pillar of the End TB 
strategy.
However, work has so far relied on cross- sectional and 
aggregate data, meaning it has not been able to track the 
pathways of individuals as they interact with the health 
system. This makes it hard to investigate the key issue of 
delays prior to diagnosis. It also means it is not possible to 
understand patterns of referral between levels of facilities, 
the true complexity and heterogeneity of patient path-
ways, or the factors that influence these. Going beyond 
capacity alignment requires routine individual- level data 
with high coverage. Any data that include individuals’ 
interactions with the health system before a diagnosis of 
TB require a methodology to interpret these events as 
related to TB care- seeking in light of their characteris-
tics and timing. In this study, we develop a generalisable 
methodology for individual PPA that makes use of health 
insurance data and apply it to Taiwan to construct and 
analyse the care pathways of patients who ultimately were 
diagnosed and treated for TB.
MeTHods
setting
TB incidence in Taiwan has been declining: from 64 cases 
per 100 000 in 2007 to 38 per 100 000 in 2018. Among 
the incident cases in 2018, less than 1.3% of cases were 
MDR- TB and around 4.9% of cases were extrapulmo-
nary TB.15 Since 2008, more than 50% of TB cases were 
aged 65 years or above, and this proportion is growing.16 
Taiwan is a high- income country and its healthcare system 
is fully integrated with the National Health Insurance 
(NHI) programme. The NHI is compulsory (over 98% 
enrolment in 2017) and covers most essential health-
care services in both public and private sectors. The 
National Health Insurance Research Database (NHIRD) 
comprises records of all healthcare claims (eg, diagnos-
tics and medications) funded by the NHI. For TB, the 
NTP covers TB diagnosis copayments and treatment and 
provides social support for essential household expend-
iture.17
data
A simple random sample of one million individuals from 
the NHIRD between 1996 and 2000 was linked to data 
beyond this period on individual characteristics (age and 
sex), healthcare records and healthcare facilities visited.18 
The main reason for clinical visits and clinicians’ diag-
noses on prescription are recorded in the NHIRD using 
the International Classification of Diseases, Ninth Revi-
sion, Clinical Modification (ICD-9- CM).
The NHIRD was provided by the NHI Administration, 
Ministry of Health and Welfare and managed by National 
Health Research Institutes (registered number 100290). 
The interpretation and conclusions contained herein do 
not represent those of the NHI Administration, Ministry 
of Health and Welfare or National Health Research 
Institutes.
Construction of individual patient pathways
In constructing individual patient pathways, we sampled 
individual patients who met previously validated criteria 
for TB diagnosis between 2003 and 2010.19 We assumed 
their care- seeking began within 3 years prior to diagnosis 
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Table 1 Logistic regression analysis of risk factors for interrupted evaluation
Factors Number IE (%) Crude OR (95% CI) Adjusted OR (95% CI)
P value (Wald's 
test)
P value (LR 
test)
All 7255 1125 (16)
Age (years) <0.001
  0-14 36 4 (11) 1.18 (0.41 to 3.34) 0.97 (0.33 to 2.8) 0.952
  15-64 3558 342 (10) Reference
  65+ 3661 779 (21) 2.54 (2.22 to 2.91) 2.42 (2.1 to 2.8) <0.001
Sex 0.817
  Female 2158 315 (15) Reference
  Male 5097 810 (16) 1.11 (0.96 to 1.27) 0.98 (0.85 to 1.14) 0.817
Area <0.001
  Centre 1332 234 (18) Reference
  East 419 76 (18) 1.04 (0.78 to 1.38) 1.12 (0.83 to 1.51) 0.458
  Kaohsiung City 1507 267 (18) 1.01 (0.83 to 1.23) 1.09 (0.89 to 1.33) 0.419
  North 740 98 (13) 0.72 (0.55 to 0.92) 0.77 (0.59 to 1) 0.054
  South 1087 179 (16) 0.93 (0.75 to 1.15) 0.95 (0.76 to 1.19) 0.672
  Taipei City 2170 271 (12) 0.67 (0.55 to 0.81) 0.75 (0.62 to 0.92) 0.005
Comorbidity
  CLD 1192 277 (23) 1.86 (1.6 to 2.17) 1.91 (1.62 to 2.24) <0.001 <0.001
  DM 1191 136 (11) 0.66 (0.55 to 0.8) 0.64 (0.53 to 0.78) <0.001 <0.001
  HIV 30 4 (13) 0.84 (0.29 to 2.4) 1.52 (0.51 to 4.49) 0.451 0.472
Initial level <0.001
  A 3104 539 (17) Reference
  B 1275 203 (16) 0.9 (0.76 to 1.08) 0.78 (0.65 to 0.93) 0.007
  C 1644 210 (13) 0.7 (0.59 to 0.83) 0.68 (0.57 to 0.82) <0.001
  D 1232 173 (14) 0.78 (0.65 to 0.94) 0.75 (0.62 to 0.92) 0.005
Pathway overlaps 
2003
2110 493 (23) 2.18 (1.91 to 2.48) 2.32 (2.02 to 2.66) <0.001 <0.001
Healthcare facility levels: A, for primary care/ general practice; B, for regional hospitals with inpatient capacity; C, for larger district 
hospitals; D, for large hospitals with a range of specialists.
Comorbidities and pathway overlaps 2003 are binary variables, applying 'none' as the reference groups.
Crude and adjusted ORs were calculated from the results of univariate and multivariate logistic regressions, respectively.
CLD, chronic lung disease; DM, diabetes mellitus; IE, interrupted evaluation; LR, likelihood ratio.
and thus used their insurance records starting from 2000 
in the following three- step analysis. First, we introduced a 
dynamic three- dimensional patient state with dimensions 
related to evaluation, treatment and clinician considera-
tion of related illnesses (all with default values of zero). 
Second, this state was used to parse sets of records into 
separate episodes of TB- related care (periods with ≥1 
state non- zero; see figure 1). Third, the state values were 
used to interpret and label the stages of each episode, 
resulting in a pathway. The Taiwan Centers for Disease 
Control (CDC) guidelines,20 WHO guidelines21 and 
expert opinion on current clinical practice were used to 
define the algorithm for state transitions and stage label-
ling (see online supplementary appendix 1). In the rest 
of this section, we describe this approach in more detail.
The evaluation dimension represents the use of diag-
nostic procedures relevant to differential diagnosis of 
TB. Evaluation tools were ranked as probably for TB and 
possibly for TB according to how specific their use was to 
TB. Evaluation possibly for TB was triggered by various 
tools for examining the respiratory system and antibi-
otics for pneumonia. Evaluation probably for TB was trig-
gered by the use of tools, including chest CT scan, chest 
X- ray, acid- fast bacteria culture, Mycobacterium tuberculosis 
culture and tuberculin skin tests (see online supplemen-
tary appendix 1 for detailed definitions).
The treatment dimension represents the use of anti- TB 
drugs. In accordance with Taiwan CDC guidelines, 
anti- TB treatment requires more than two types of anti- TB 
drugs prescribed continuously for at least 4 weeks. Treat-
ment was either first- line or second- line according to the 
drugs prescribed (see online supplementary appendix 
1). We did not consider multidrug- resistant (MDR)- TB 
separately.
The related illness dimension captures potential clini-
cian consideration of alternative diagnoses. Increased 
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Figure 2 Alignment between the capacity for TB diagnosis 
and treatment, and patients’ preferences in seeking care 
hospital levels: A, for primary care/general practice; B, for 
regional hospitals with inpatient capacity; C, for larger district 
hospitals; D, for large hospitals with a range of specialists. 
(A) Coverage of and access to TB services at different levels 
of Taiwan’s health system modiied. This panel is a modiied 
version of the visualisation introduced by Hanson et al.7 
Coverage is the proportion of facilities at that level offering a 
service; access is the product of coverage and the fraction 
of patients seeking care at that level. (B) Patient lows 
between levels at each stage, including clinician referral and 
self- referral (vertical heights of bands are proportional to 
numbers). TB, tuberculosis.
Figure 3 Delays from initial care- seeking; the curves 
indicate the proportion of pathways by time that have 
reached hospitals providing TB treatment (red); reached the 
hospital, which ultimately initiates their TB treatment (blue); 
and started treatment (green). The vertical line on day 41 
denotes the median system delay. TB, tuberculosis.
values were triggered by features, including ICD-9- CM 
codes corresponding to acute respiratory infections, 
chronic lung diseases and non- tuberculous mycobacte-
rial infections.
Each state’s value could return to zero after a ‘time- out’ 
period if no relevant trigger records occurred. A patient’s 
treatment state also returned to zero after treatment 
completion. The choice of time out sets a memory times-
cale beyond which records no longer influence a patient’s 
state. The default time out was 60 days, and sensitivity 
analyses used 30, 90 and 120 days.
Care- seeking episodes were defined as collections of 
records including anti- TB treatment (excluding explor-
atory treatment), during which a patient’s state was 
continuously above zero in at least one dimension, sepa-
rated by periods with all dimensions equal to zero (see 
figure 1). Initial care- seeking is defined as the start of 
a care- seeking episode. Episodes could include records 
related to care- seeking prior to TB diagnosis. Without 
evidence that alternative diagnoses were being actively 
considered (ie, related illness state and evaluation state 
both return to zero), prior evaluations are dropped from 
an episode (figure 1B). If there was evidence of ongoing 
consideration of alternative diagnoses to TB (non- zero- 
related illness state), diagnostic procedures relevant to 
TB would be included in the episode even if the evalua-
tion state returned to zero in the interim (figure 1C); this 
is termed an ‘interrupted evaluation’.
To complete pathway construction, time within 
parsed episodes was labelled as one of four main stages 
according to the values of the state (figure 1, background 
colours): waiting stage (before evaluation), evaluating 
stage (under evaluation for possible TB), TB detecting 
stage (under evaluation for probable TB) and treating 
stage (on TB treatment).
Analyses of individual patient pathways
We calculated descriptive statistics including the number 
of pathways, in total, and by gender and age.
Individual patient pathways were analysed to under-
stand the coverage of services at different levels of the 
health system and referral patterns between them. We 
extracted the list of hospitals with captured events from 
the patient pathways. Hospitals were classified into one 
of four levels following a standard classification (A for 
primary care/general practice, B for regional hospitals 
with inpatient capacity, C for larger district hospitals and 
D for large hospitals with a range of specialists). We then 
calculated the ‘coverage’ of each service at a given level 
of facilities (the proportion of facilities of the given level 
where the service was available), as well as the patient 
‘access’ to these services (proportions of levels of hospi-
tals where patients initially sought care). We summarised 
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Figure 4 Cumulative pathway typology before and after 
treatment initiation. The aggregated number of pathways 
with a given sequence of stages (Y axis) versus the 
proportion of their time in each stage (X axis). (A) Sequence 
patterns before treatment initiation. (B) Sequence patterns 
from treatment initiation to treatment outcome. Completed: 
treatment period longer than 180 days; censored: end with 
the end of data time frame. See article text and online 
supplementary appendix 5 for stage deinitions. LTFU, 
lost to follow- up, incomplete treatment for no reason; TB, 
tuberculosis.
Figure 5 Time from initial care- seeking to given care 
stage completed: treatment period longer than 180 days. 
Censored: end with the end of data time frame. See 
article text and online supplementary appendix 5 for stage 
deinitions. LTFU, lost to follow- up, incomplete treatment for 
no reason; TB, tuberculosis.
these metrics with a modified version of the PPA visuali-
sation introduced by Hanson et al.7 We also visualised the 
flow of patients between health service levels by pathway 
stage. We computed the distribution of delays from initial 
care- seeking to first reaching facility with anti- TB treat-
ment capacity, to first reaching the facility where ulti-
mately treated and to treatment initiation. System delay 
refers to the period between initial care- seeking to treat-
ment initiation.
The heterogeneity in patient pathway complexity and 
time spent in different stages was visualised by sequence 
frequency plots, separately for subpathways leading up 
to and following treatment. To summarise time taken to 
reach a given stage of care, we also visualised the number 
of pathways reaching a given substage by time after initial 
care- seeking. We calculated the proportions of all clin-
ical encounters among the pathways with the 10% least 
common sequence patterns; of these pathways for which 
treatment started over 1 year after initial care- seeking 
and of all pathways experiencing interrupted evaluation. 
Finally, we analysed risk factors, including age, sex, area, 
comorbidity and hospitals at initial care- seeking for inter-
rupted evaluation using logistic regression.
The pathway extraction was performed in Python V.3.6; 
statistical analysis and visualisation were performed in R 
V.3.5.1 and ggplot2. See source code (https:// github. 
com/ Pati entP athw ayAn alysis/ IPPA- py), online supple-
mentary appendices 2 and 4 for implementation detail, 
links in online supplementary appendix 6 for online 
documents and related code repositories.
resulTs
A total of 6258 patients met our criteria for TB between 
2003 and 2010. Our algorithm generated 7255 distinct 
pathways for these patients: 88% of patients had only one 
pathway. The use of longer time outs resulted in fewer 
distinct pathways: 7528 for 30 days, 6963 for 90 days and 
6831 for 120 days (see online supplementary appendix 
3, sensitivity analysis). Men contributed 70% of patient 
pathways; 50.5%, 49% and 0.5% of pathways were from 
those aged over 65, between 15 and 64, and below 14 
years, respectively. Around 16% of patient pathways 
involved those with chronic lung conditions. Lastly, over 
50% of patient pathways occurred in the two major cities: 
Taipei City and Kaohsiung City (see the first column of 
table 1).
Coverage and access by level of the health system 
are shown in figure 2A. Initial care- seeking was most 
common at level A, but further evaluations and treat-
ment rarely occurred at this level; only a minority of these 
facilities (around 15%) had the capacity for TB diagnosis 
and treatment, as shown in the bottom row of figure 2A. 
Coverage at facility levels higher than A exceeded 93%. 
Figure 2B shows the associated flow of patients between 
levels of the health system, with an upwards flow across 
all stages. Around 50% of patient pathways began at level 
A or B (36% where TB treatment was unavailable), but 
over 74% of pathways initiated treatment at level C or D.
Delays from initial care- seeking to a facility offering 
TB treatment, the facility ultimately providing treatment 
and treatment initiation are shown in figure 3. Sixteen 
per cent of pathways initiated treatment at their initial 
visit. By day 60, TB treatment was available for 90% of the 
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pathways and 80% had arrived at the facilities ultimately 
providing their treatments. By day 180, 84% of pathways 
had started treatment. The median system delay (from 
initial care- seeking to treatment initiation) was 41 days.
The typology of pathways before and after treatment 
start is shown in figure 4. Before treatment starts, simpler 
pathways were most common. Second- line anti- TB treat-
ments (including fluoroquinolones) were used in 34% of 
pathways. However, the most complex pathways (ie, path-
ways with the rarest 10% of sequence types; see figure 4) 
exhibited intricate patterns of evaluation interruptions 
and re- evaluations; 100% of these pathways included 
interrupted evaluation.
The pattern of delays from initial care- seeking to later 
stages of care is shown in figure 5, truncated at 1 year. The 
long tail of 7% of pathways yet to start treatment a year 
after initial care- seeking is clearly visible. One year after 
initial care- seeking, 21% of pathways were still on TB 
treatment (40% of these on second- line treatment); 41% 
had completed treatment; 18% were lost to follow- up; 
and 10% of patients had died. Fifty- five per cent of the 
10% of most complex pathways were yet to initiate treat-
ment a year after initial care- seeking.
Interrupted evaluation occurred in 16% of all pathways, 
but these pathways included 48% of all visits/records and 
comprised a majority of the most complex and delayed 
pathways (see previous discussion). The median delay 
from initial care- seeking to treatment initiation in path-
ways with interrupted evaluation was 313 days (interquar-
tile interval 164–607 days). Table 1 shows that pathways 
for patients aged 65 years or older (OR 2.4, 95% CI 2.1 
to 2.8) compared with patients aged 15–64 years, those 
with chronic lung disease (OR 1.9, 95% CI 1.6 to 2.2), 
and pathways which included 2003 (the year of the severe 
acute respiratory syndrome (SARS) epidemic) (OR 2.3 
95% CI 2.0 to 2.7) were significantly more likely to expe-
rience interrupted evaluation. Pathways for patients with 
diabetes mellitus (DM) and who sought care at hospitals 
higher than level A were significantly less likely to include 
interrupted evaluation (OR 0.64, 95% CI 0.53 to 0.78).
dIsCussIon
In this study, we constructed individual patient path-
ways of TB care- seeking, diagnosis and treatment using 
routine NHI data in Taiwan. To do this, we developed a 
generalisable method to algorithmically interpret insur-
ance claim records in light of the context of previous and 
future events on the pathway. This approach was neces-
sary in order to determine whether healthcare use prior 
to eventual diagnosis was in fact related to a given TB 
episode. Even in this well- resourced setting, there is low 
apparent coverage of TB care capacity at the lowest- level 
facilities where patients most commonly started seeking 
care, and substantial heterogeneity in the duration and 
complexity of TB- related care pathways.
The most complex patient experiences and the most 
prolonged delays prior to treatment were associated with 
what we have termed interrupted evaluations. These path-
ways are those that include unusually long delays between 
the first relevant diagnostic procedure and TB diagnosis, 
as well as evidence that alternative causes of disease are 
being considered. Interestingly, our regression analysis 
showed that patients with DM were significantly less likely 
to experience interrupted evaluation, perhaps indicating 
an awareness among clinicians of DM as a risk factor for 
TB. However, patients whose care- seeking overlapped 
with the 2003 SARS epidemic, patients who had chronic 
lung disease or patients aged 65 years or above were all 
significantly more likely to experience interrupted eval-
uation. The SARS epidemic may have shifted attention 
towards alternative aetiologies of respiratory symptoms, 
as well as potentially generating increases in caseload that 
distorted usual practice. Comorbid chronic lung disease 
may have obscured TB symptoms, which would be unfor-
tunate as chronic lung disease (eg, chronic obstructive 
pulmonary disorder) shares risk factors with TB and 
may causally increase the likelihood of TB and worsen 
outcomes.22–24 Lastly, differential diagnosis of TB may be 
more complex for older adults, and successful treatment 
is more challenging.25
In addition to service coverage, we were also able to 
analyse the referral flows of patients between different 
levels of the healthcare system. We found a general trend 
for escalation in level from initial care- seeking, with most 
patients seeking care at lower levels and most being 
treated at higher levels. While coverage of TB services was 
very high except at the lowest level, 36% of first attempts 
to seek care were still at facilities without the capacity to 
diagnose or treat TB. Patients did rapidly reach facili-
ties where TB treatment was available, but 34% initiated 
treatment at a facility other than the first one they visited 
offering TB treatment, and the median delay between 
arriving at the facility where they were treated and treat-
ment initiation was 6 days. These features may represent a 
lack of confidence or familiarity in diagnosing TB among 
clinicians at the primary care level. Further investigations 
to understand the reasons for this are warranted.
Our work builds on the PPA introduced in a series 
of recent papers.7–13 We were able to obtain similar 
outputs, including similar conclusions around coverage 
at the facility level typical of initial visits, but there are a 
number of differences which stem from our use of longi-
tudinal individual- level data. Our coverage statistics for 
the availability of diagnosis at facilities are based not on 
direct facility data but on inferred availability from events 
in patient records. This will underestimate the actual 
coverage at facilities where tools are available but have 
not been used for patients in our data. This is likely to be 
particularly true at the lowest level of care. Importantly, 
our definition of ‘initial care- seeking’ differs from that 
used up to now in PPA, where initial care- seeking refers 
to patients’ preferred location to first access care for 
symptoms related to TB, determined from retrospective 
surveys.7 Our initial care- seeking events need not involve 
the initiation of care; indeed, multiple visits are typical 
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between initial care- seeking and treatment initiation, 
including missed opportunities for earlier diagnosis. Our 
approach to identifying care- seeking related to a partic-
ular TB episode also differs from that used in Chen et 
al19 due to the potential for interrupted evaluation. This 
is why our median delay from initial visit to treatment 
(41 days) is somewhat longer than theirs (29 days) and 
longer than the median health system delay reported by 
a systematic review.26
Opportunities to validate our estimates are limited by 
their novelty. However, Taiwan CDC reported national 
treatment outcomes for 2010 as 71.1% treatment success 
and 20.2% death.27 Our analysis, based on a sample 
of cases in 2003–2010 classified 66.1% of pathways as 
ending with treatment completion and 14.2% with death. 
For both analyses, over 80% of deaths were among those 
aged 65 years.
The key strengths of this work lie in the use of individual- 
level data from a large population- representative sample, 
and the analyses of heterogeneity, referral patterns and 
determinants that this allowed. Due to the compulsory 
NHI system, we had data available to us relating to essen-
tially all clinical encounters over a long period of time 
in individuals diagnosed with TB. Through our algo-
rithm, we were able to identify early TB care- seeking 
events prior to diagnosis and analyse their patterns. It 
has been argued that the correct start- point for cohort- 
based analysis of patient care is the initial attempt to seek 
care rather than successful diagnosis or treatment initia-
tion.6 However, this has previously relied predominantly 
on experiences reported retrospectively by patients,26 
which are subject to recall biases. We were also able to 
link patient- level covariates, including comorbidities for 
risk factor analysis.
The main limitations of our analysis are around the 
nature of routine data, and the assumptions needed 
by any algorithm to interpret these records in terms 
of TB- related care- seeking. For example, our choice 
of time- out period to determine whether respiratory- 
related care- seeking events were part of a TB patient 
pathway affects how protracted and fragmented pathways 
are prior to diagnosis. The initial value of 60 days was 
based on a previous study evaluating health system delay 
of TB diagnosis in Taiwan.19 However, sensitivity analyses 
varying the choice of time- out showed that our main 
conclusions were not substantially affected. We relied on 
clinician coded ICD-9- CM codes to characterise clinical 
encounters; there may have been miscoding or omission 
of relevant secondary diseases for multimorbid patients. 
The choices of timings characterising treatments were 
based on standard treatment and may not have applied 
to extrapulmonary TB, although rates of extrapulmonary 
TB are low in Taiwan. In addition, our methods may work 
less well for TB patients with underlying chronic lung 
disease, for which they also interact with health services. 
Finally, our analysis cannot account for the delay between 
the start of infectiousness or symptoms and initial care- 
seeking. Prevalence- to- notification ratios in high TB 
burden settings typically correspond to a mean disease 
duration over a year,28 29 whereas the predominant 
approaches to measuring delays by asking patients typi-
cally result in shorter delays of the order 6 months.26 Our 
analysis sheds light on the health system delay contribu-
tion in this setting (from care- seeking to diagnosis) and 
suggests mean durations are strongly influenced by the 
few individuals with very long delays.
We developed our approach to analysing patient- level 
routine data using health insurance data for Taiwan, but 
this analysis framework could be adapted and applied to 
other settings and conditions. The prerequisite for this 
analysis is individual- level high- coverage routine data on 
healthcare use, ideally beyond services specific to the 
condition of interest. While such data are still relatively 
rare in many low- income and middle- income settings, 
health informatics systems are improving, for example, 
the wider use of electronic case- based notification 
systems for TB, and there are subnational linkage efforts 
that may allow such an analysis at a more local level.30 Use 
of different diagnostic codes for TB, different locally rele-
vant comorbidities (eg, HIV) and clinical practices could 
all be included by adapting the open source code for 
our analysis. Likewise, consideration should be given to 
different time- out values as these are inevitably related to 
a system and patient characteristics. Future work building 
on our analysis for TB in Taiwan will include analysis 
considering health system costs and patient prescription 
charges, analysis with respect to proxy measures of socio-
economic status and developing simulation models repli-
cating observed patterns of patient care- seeking.
ConClusIon
Our study demonstrates that longitudinal analysis of 
routine individual- level healthcare data can be used to 
generate a detailed picture of TB care- seeking pathways. 
This allows an understanding of several temporal aspects 
of care pathways, including lead times to care and the 
variability in patient pathways. Analysis of Taiwanese 
patient pathways suggests improved capacity to refer 
diagnostic specimens from peripheral healthcare facili-
ties could simplify patient access to TB care.
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